JCI Editorial Board
potential first-tier conflicts of interest

Updated May 11, 2022

Go to the JCI's conflict-of-interest policy

AbbVie (A.B. Heimberger)

AccureX (D. Krainc)

Actuate Therapeutics (S.A. Abdulkadir)

Arvinas (M. Hussain)

Astellas Pharma (S.A, Abdulkadir)

AstraZeneca (M. Hussain)

Bayer (M. Hussain)

Boehringer Ingelheim (G.D. Barish)

Caris Life Sciences (A.B. Heimberger)

Celularity (A.B. Heimberger)

Codiak (A.B. Heimberger)

Genentech (M. Hussain)

Google (J. Choi)

Inomagen Therapeutics Inc. (R. Arora)

Intellia Therapeutics (D. Krainc)

Ionis (J. Bass)

Intellia Therapeutics (D. Krainc)

Mannin Research Inc. (S.E. Quaggin)

Medtronic (J. Bass)

Merck (A.B. Heimberger)

Nfold (S. Eisenbarth)

OrbiMed Advisors (D. Krainc)

Parexel (S. Bulun)

Pfizer (N.S. Chandel)

Praxis Precision Medicines (A.L. George Jr.)

Rafael Pharmaceuticals (N.S. Chandel)

Regeneron (J. Bass)

Roche (S.E. Quaggin)

Tevard Biosciences (A.L. George Jr.)

Thermo Fisher Scientific (J. Bass)

Vertex (J. Bass)

Vortex Biosciences (S.A, Abdulkadir)

WCG (A.B. Heimberger)

Yumanity Therapeutics (A.B. Heimberger)

Vanqua Bio (D. Krainc)